Genentech - more more more

A special committee of Genentech's board of directors said it recommended that its shareholders reject Roche's latest offer of $86.50 per share. Charles Sanders, chairman of the Genentech committee evaluating the bid, commented that "Genentech's strong projected financial performance implies a valuation substantially in excess of Roche's offer price."